Syros Pharmaceuticals (LTS:0LC7) Total Noninterest Expense

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0LC7 Syros Pharmaceuticals Inc LTS:0LC7
12 GF Score
Price $0.00
View Full Analysis

What is Syros Pharmaceuticals Total Noninterest Expense?

Total Noninterest Expense only applies to banks.

LTS:0LC7
12GF Score
Syros Pharmaceuticals Inc LTS:0LC7
Total Noninterest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Syros Pharmaceuticals Business Description

Address 35 CambridgePark Drive, 4th Floor, Cambridge, MA, USA, 02140
Syros Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in the United States that develops small-molecule medicines for cancer, with a focus on hematologic malignancies and breast cancer. Its pipeline has centered on therapies targeting transcriptional regulation, including tamibarotene, an oral selective retinoic acid receptor alpha agonist studied in acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, an oral CDK7 inhibitor. The company also has a history of developing gene-control therapies directed at cancer stem cells and other targets. Syros generates no product revenue, as none of its drug candidates has received regulatory approval; it funds operations primarily through equity financings, collaborations, and licensing arrangements. Its activities span preclinical research through clinical trials conducted at medical centers in the United States, with development efforts aimed at patient populations defined by specific genetic biomarkers.
12GF Score

Get the complete analysis for LTS:0LC7

Total Noninterest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price